Active duty service members and veterans with post-traumatic stress disorder (PTSD) refractory to evidence-based therapy were randomized to receive either riluzole, a glutamate modulator, or placebo adjunctive to selective serotonin reuptake inhibitor therapy over an 8-week period. Subjects underwent 1H brain magnetic resonance spectroscopy scans pre- and post-treatment and were assessed longitudinally for PTSD symptomology using the Clinician-Administered PTSD Scale (CAPS). Subjects were stratified into improved and non-improved groups based on a decrease in CAPS score. Analyses on within- and between-group metabolite differences revealed that riluzole modulated the glutamate-glutamine cycle, improved neural energetics, and may have induced choline-linked neuroprotective inflammation.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords